Evidence map›Paper›PMID 29016749›Full record

ReviewCardiovascular research2017

Differential eNOS-signalling by platelet subpopulations regulates adhesion and aggregation.

Aneta Radziwon-Balicka, Gabriela Lesyk, Valentina Back, Teresa Fong, Erica L Loredo-Calderon, Bin Dong, Haitham El-Sikhry, Ahmed A El-Sherbeni, Ayman El-Kadi, Stephen Ogg and 7 more

Open access · bronzeAbstract readReview
In one paragraph

Review in Cardiovascular research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Nanomaterials-Based Immunotherapy for Atherosclerosis.Small (Weinheim an der Bergstrasse, Germany) · 2026
    Review
  3. Redox Control in Platelet Activity and Therapy.Antioxidants (Basel, Switzerland) · 2025
    Review
  4. Article
  5. Review
  6. Subcellular Localization Guides eNOS Function.International journal of molecular sciences · 2024
    Review
  7. Review
  8. SDMA as a marker and mediator in cerebrovascular disease.Clinical science (London, England : 1979) · 2024
    Review
  9. Review
  10. Heterogeneity of platelets and their responses.Research and practice in thrombosis and haemostasis · 2024
    Article
  11. Article
  12. Role of Nitric Oxide in Megakaryocyte Function.International journal of molecular sciences · 2023
    Review
  13. Platelets and Cardioprotection: The Role of Nitric Oxide and Carbon Oxide.International journal of molecular sciences · 2023
    Review
  14. Platelets in COVID-19 disease: friend, foe, or both?Pharmacological reports : PR · 2022
    Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 2 countries.

Aneta Radziwon-BalickaFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G-2E1, Canada.
Gabriela LesykFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G-2E1, Canada.
Valentina BackFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G-2E1, Canada.
Teresa FongFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G-2E1, Canada.
Erica L Loredo-CalderonFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G-2E1, Canada.
Bin DongNeurochemical Research Unit, Department of Psychiatry, University of Alberta, Edmonton, AB T6G-2R3, Canada.
Haitham El-SikhryFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G-2E1, Canada.
Ahmed A El-SherbeniFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G-2E1, Canada.
Ayman El-KadiFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G-2E1, Canada.
Stephen OggDepartment of Medical Microbiology and Immunology, University of Alberta Edmonton, AB T6G-2E1, Canada.
Arno SirakiFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G-2E1, Canada.
John M SeubertFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G-2E1, Canada.
Maria Jose Santos-MartinezSchool of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland.
Marek W RadomskiCollege of Medicine, University of Saskatchewan, Saskatoon, SK S7N-5E5, Canada.
Carlos A Velazquez-MartinezFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G-2E1, Canada.
Ian R WinshipNeurochemical Research Unit, Department of Psychiatry, University of Alberta, Edmonton, AB T6G-2R3, Canada.
Paul JuraszFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G-2E1, Canada.
University of Alberta · CATrinity College Dublin · IEUniversity of Saskatchewan · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsIn addition to maintaining haemostasis, circulating blood platelets are the cellular culprits that form occlusive thrombi in arteries and veins. Compared to blood leucocytes, which exist as functionally distinct subtypes, platelets are considered to be relatively simple cell fragments that form vascular system plugs without a differentially regulated cellular response. Hence, investigation into platelet subpopulations with distinct functional roles in haemostasis/thrombosis has been limited. In our present study, we investigated whether functionally distinct platelet subpopulations exist based on their ability to generate and respond to nitric oxide (NO), an endogenous platelet inhibitor. METHODS AND

resultsUtilizing highly sensitive and selective flow cytometry protocols, we demonstrate that human platelet subpopulations exist based on the presence and absence of endothelial nitric oxide synthase (eNOS). Platelets lacking eNOS (approximately 20% of total platelets) fail to produce NO and have a down-regulated soluble guanylate cyclase-protein kinase G (sGC-PKG)-signalling pathway. In flow chamber and aggregation experiments eNOS-negative platelets primarily initiate adhesion to collagen, more readily activate integrin αIIbβ3 and secrete matrix metalloproteinase-2, and form larger aggregates than their eNOS-positive counterparts. Conversely, platelets having an intact eNOS-sGC-PKG-signalling pathway (approximately 80% of total platelets) form the bulk of an aggregate via increased thromboxane synthesis and ultimately limit its size via NO generation.

conclusionThese findings reveal previously unrecognized characteristics and complexity of platelets and their regulation of adhesion/aggregation. The identification of platelet subpopulations also has potentially important consequences to human health and disease as impaired platelet NO-signalling has been identified in patients with coronary artery disease.

Indexed as

AnimalsBlood PlateletsHumansMatrix Metalloproteinase 2Nitric OxideNitric Oxide Synthase Type IIIPlatelet AggregationPlatelet Aggregation InhibitorsMatrix Metalloproteinase 2Nitric OxideNitric Oxide Synthase Type IIIPlatelet Aggregation InhibitorsAggregationEndothelial nitric oxide synthaseFlow cytometryNitric oxidePlatelet subpopulations

Identifiers

PMID29016749
PMCPMC5852541
OpenAlexW2753180280

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.